Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031)
Status:
Completed
Trial end date:
2014-11-03
Target enrollment:
Participant gender:
Summary
This study aims to demonstrate that, when given concomitantly with a 5-hydroxytryptamine 3
(5-HT3) antagonist and a corticosteroid, a single 150 mg intravenous (IV) dose of
fosaprepitant given on Day 1 is superior to the control regimen of 5-HT3 antagonist and
corticosteroid only, in preventing chemotherapy-induced nausea and vomiting (CINV) associated
with moderately emetogenic chemotherapy (MEC).